Deficiency of SPARC suppresses intestinal tumorigenesis in APC Min/+ mice

Gut

Volumn 56, Issue 10, 2007, Pages 1410-1414

  Sansom, Owen J ^a   Mansergh, Fiona C ^b   Evans, Martin J ^b   Wilkins, Julie A ^a   Clarke, Alan R ^b  

^a BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; OSTEONECTIN; RNA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CARCINOGENESIS; CELL MIGRATION; COLON MUCOSA; COLON POLYPOSIS; COLORECTAL CANCER; IN VIVO STUDY; INTESTINE; INTESTINE CELL; INTESTINE TUMOR; KNOCKOUT MOUSE; LABELING INDEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEFICIENCY; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; UPREGULATION;

ADENOCARCINOMA; ADENOMA; ANIMALS; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; COLON; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; ENTEROCYTES; INTESTINAL NEOPLASMS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; OSTEONECTIN; POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; UP-REGULATION;

EID: 34948896375     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.116921     Document Type: Article

References (24)

1. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004;92:679-690.
2. Schiemann BJ, Neil JR, Schiemann WP. SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signalling system. Mol Biol Cell 2003;14:3977-3988.
3. Brabender J, Lord RV, Metzger R, et al. Differential SPARC mRNA expression in Barrett's oesophagus. Br J Cancer 2003;89:1508- 1512.
4. Wang CS, Lin KH, Chen SL, et al. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004;91:1924-1930.
5. Takemasa I, Higuchi H, Yamamoto H, et al. Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. Biochem Biophys Res Commun 2001;285:1244-1249.
6. Boon K, Edwards JB, Eberhart CG, et al. Identification of astrocytoma associated genes including cell surface markers. BMC Cancer 2004;4:39.
7. Nakada M, Miyamori H, Yamashita J, et al. Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins. Cancer Res 2003;63:3364-3369.
8. Genini M, Schwalbe P, Scholl FA, et al. Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma. Int J Cancer 1996;66:571-577.
9. Gilmour DT, Lyon GJ, Carlton MB, et al. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J 1998;17:1860-1870.
10. Reed KR, Sansom OJ, Hayes AJ, et al. PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 2004;23(55):8992-8996.
11. Sansom OJ, Griffiths DF, Reed KR, et al. Apc deficiency predisposes to renal carcinoma in the mouse. Oncogene 2005;24:8205-8210.
12. Martinez C, Bhattacharya S, Freeman T, et al. Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes. J Pathol 2005;206:100-110.
13. Norose K, Clark JI, Syed NA, et al. SPARC deficiency leads to early-onset cataractogenesis. Invest Ophthalmol Vis Sci 1998;39:2674-2680.
14. Brekken RA, Puolakkainen P, Graves DC, et al. Enhanced growth of tumors in SPARC null mice is associated with changes in the 17 ECM. J Clin Invest 2003;111:487-495.
15. Puolakkainen PA, Brekken RA, Muneer S, et al. Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol Cancer Res 2004;2:215-224.
16. Sangaletti S, Stoppacciaro A, Guiducci C, et al. Leukocyte, rather than tumor-produced SPARC, determines stroma and collagen type IV deposition in mammary carcinoma. J Exp Med 2003;198:1475-1485.
17. Rao CV, Yang YM, Swamy MV, et al. Colonic tumorigenesis in BubR1+/ -ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proc Natl Acad Sci U S A 2005;102:4365-4370.
18. Cormier RT, Hong KH, Halberg RB, et al. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. Nat Genet 1997;17:88-91.
19. Clarke AR, Cummings MC, Harrison DJ. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 1995;11:1913-1920.
20. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest 2001;107:785-790.
21. Mahmoud NN, Dannenberg AJ, Mestre J, et al. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998;124:225-231.
22. Mahmoud NN, Bilinski RT, Churchill MR, et al. Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. Cancer Res 1999;59:353-359.
23. Fenton JI, Wolff MS, Orth MW, et al. Membrane-type matrix metalloproteinases mediate curcumin-induced cell migration in non-tumorigenic colon epithelial cells differing in Apc genotype. Carcinogenesis 2002;6:1065-1070.
24. Puolakkainen PA, Bradshaw AD, Brekken RA, et al. SPARC-thrombospondin-2-double-null mice exhibit enhanced cutaneous wound healing and increased fibrovascular invasion of subcutaneous polyvinyl alcohol sponges. J Histochem Cytochem 2005;53:571-581.